Sarepta shares up more than 10% as results beat expectations, drug gets priority consideration

Shares of Sarepta Therapeutics Inc. SRPT rose in an extended session on Tuesday after the biotech maker beat Wall Street’s expectations and said US regulators had granted priority review status to its muscular dystrophy drug candidate SRP-9001. Shares of Sarepta rose 14% after hours after rising 3.3% in the regular session to close at $122.13. The company reported a fourth-quarter loss of $109.2 million, or $1.24 per share, compared to a loss of $122 million, or $1.42 per share, a year earlier. The adjusted loss, excluding compensatory expenses on shares and other items, was 53 cents…

Content Source

News Press Ohio – Latest News:
Columbus Local News || Cleveland Local News || Ohio State News || National News || Money and Economy News || Entertainment News || Tech News || Environment News

Related Articles

Back to top button